Disease severity, e.g., disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS) in lungs, cardiovascular injuries (ischemia, pulmonary thromboembolism, and deep venous thrombosis), and cerebral infarctions (embolism) due to SARS-CoV-2 virus, cannot be anticipated with certainty using laboratory biomarkers for D-dimer, prothrombin time (PT), and activated partial thromboplastin time (aPTT) [7]. This evidence concerns the gene F2 and acute respiratory distress syndrome.